|
1
|
Karpińska K, Gielata M, Gwiazdowska A, Boryń Ł, Kobielak A. Catulin Based Reporter System to Track and Characterize the Population of Invasive Cancer Cells in the Head and Neck Squamous Cell Carcinoma. Int J Mol Sci 2021; 23:ijms23010140. [PMID: 35008571 PMCID: PMC8745103 DOI: 10.3390/ijms23010140] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Revised: 12/20/2021] [Accepted: 12/21/2021] [Indexed: 12/13/2022] Open
Abstract
Head and neck squamous cell carcinoma (HNSCC) is an aggressive tumor with a poor prognosis due to late diagnosis and loco-regional metastasis. Partial or more complete epithelial-mesenchymal transition (EMT) plays a role in tumor progression; however, it remains a challenge to observe the EMT in vivo, due to its transient nature. Here, we developed a novel catulin promoter-based reporter system that allows us to isolate and characterize in vivo a small fraction of invasive cancer cells. The analyses of tumors revealed that Catulin-green fluorescent protein (GFP)-positive cells were enriched in clusters of cells at the tumor invasion front. A functional genomic study unveiled genes involved in cellular movement and invasion providing a molecular profile of HNSCC invasive cells. This profile overlapped partially with the expression of signature genes related to the partial EMT available from the single cell analysis of human HNSCC specimens, highlighting the relevance of our data to the clinical disease progression state. Interestingly, we also observed upregulations of genes involved in axonal guidance-L1 cell adhesion molecule (L1CAM), neuropilin-1, semaphorins, and ephrins, indicating potential interactions of cancer cells and neuronal components of the stroma. Taken together, our data indicated that the catulin reporter system marked a population of invasive HNSCC cells with a molecular profile associated with cancer invasion.
Collapse
Affiliation(s)
- Kamila Karpińska
- Laboratory of the Molecular Biology of Cancer, Centre of New Technologies, University of Warsaw, 00-927 Warsaw, Poland; (K.K.); (M.G.); (A.G.)
| | - Mateusz Gielata
- Laboratory of the Molecular Biology of Cancer, Centre of New Technologies, University of Warsaw, 00-927 Warsaw, Poland; (K.K.); (M.G.); (A.G.)
| | - Aleksandra Gwiazdowska
- Laboratory of the Molecular Biology of Cancer, Centre of New Technologies, University of Warsaw, 00-927 Warsaw, Poland; (K.K.); (M.G.); (A.G.)
| | - Łukasz Boryń
- Laboratory of Stem Cells, Tissue Development and Regeneration, Centre of New Technologies, University of Warsaw, 00-927 Warsaw, Poland;
| | - Agnieszka Kobielak
- Laboratory of the Molecular Biology of Cancer, Centre of New Technologies, University of Warsaw, 00-927 Warsaw, Poland; (K.K.); (M.G.); (A.G.)
- Correspondence: ; Tel.: +48-22-55-43-735
| |
Collapse
|
|
2
|
Burgy M, Jehl A, Conrad O, Foppolo S, Bruban V, Etienne-Selloum N, Jung AC, Masson M, Macabre C, Ledrappier S, Burckel H, Mura C, Noël G, Borel C, Fasquelle F, Onea MA, Chenard MP, Thiéry A, Dontenwill M, Martin S. Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2021; 13:cancers13123038. [PMID: 34207120 PMCID: PMC8235528 DOI: 10.3390/cancers13123038] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Revised: 06/06/2021] [Accepted: 06/11/2021] [Indexed: 11/17/2022] Open
Abstract
Simple Summary The EGFR-targeting antibody cetuximab (CTX) combined with radiotherapy has been proven effective for the treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Due to resistance to CTX, some patients do not benefit from the treatment and recurrence is observed. As caveolin-1 (Cav1) has been reported to affect the EGFR pathway, we aimed to elucidate how it might affect the response to CTX-radiotherapy. We showed that Cav1 expression conferred surviving, growing and motile capacities that protect cells against the combination of CTX-radiotherapy. The protecting effects of Cav1 are mediated by the Cav1/EREG/YAP axis. We also showed in a retrospective study that a high expression of Cav1 was predictive of locoregional relapse of LA-HNSCC. Cav1 should be taken into consideration in the future as a prognosis marker to identify the subgroup of advanced HNSCC at higher risk of recurrence, but also to help clinicians to choose the more appropriate therapeutic strategies. Abstract The EGFR-targeting antibody cetuximab (CTX) combined with radiotherapy is the only targeted therapy that has been proven effective for the treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Recurrence arises in 50% of patients with HNSCC in the years following treatment. In clinicopathological practice, it is difficult to assign patients to classes of risk because no reliable biomarkers are available to predict the outcome of HPV-unrelated HNSCC. In the present study, we investigated the role of Caveolin-1 (Cav1) in the sensitivity of HNSCC cell lines to CTX-radiotherapy that might predict HNSCC relapse. Ctrl- and Cav-1-overexpressing HNSCC cell lines were exposed to solvent, CTX, or irradiation, or exposed to CTX before irradiation. Growth, clonogenicity, cell cycle progression, apoptosis, metabolism and signaling pathways were analyzed. Cav1 expression was analyzed in 173 tumor samples and correlated to locoregional recurrence and overall survival. We showed that Cav1-overexpressing cells demonstrate better survival capacities and remain proliferative and motile when exposed to CTX-radiotherapy. Resistance is mediated by the Cav1/EREG/YAP axis. Patients whose tumors overexpressed Cav1 experienced regional recurrence a few years after adjuvant radiotherapy ± chemotherapy. Together, our observations suggest that a high expression of Cav1 might be predictive of locoregional relapse of LA-HNSCC.
Collapse
Affiliation(s)
- Mickaël Burgy
- Laboratory of Bioimaging and Pathology, University of Strasbourg, UMR7021 CNRS, 67401 Illkirch, France; (M.B.); (A.J.); (O.C.); (S.F.); (V.B.); (N.E.-S.); (M.D.)
- Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, France;
| | - Aude Jehl
- Laboratory of Bioimaging and Pathology, University of Strasbourg, UMR7021 CNRS, 67401 Illkirch, France; (M.B.); (A.J.); (O.C.); (S.F.); (V.B.); (N.E.-S.); (M.D.)
| | - Ombline Conrad
- Laboratory of Bioimaging and Pathology, University of Strasbourg, UMR7021 CNRS, 67401 Illkirch, France; (M.B.); (A.J.); (O.C.); (S.F.); (V.B.); (N.E.-S.); (M.D.)
| | - Sophie Foppolo
- Laboratory of Bioimaging and Pathology, University of Strasbourg, UMR7021 CNRS, 67401 Illkirch, France; (M.B.); (A.J.); (O.C.); (S.F.); (V.B.); (N.E.-S.); (M.D.)
| | - Véronique Bruban
- Laboratory of Bioimaging and Pathology, University of Strasbourg, UMR7021 CNRS, 67401 Illkirch, France; (M.B.); (A.J.); (O.C.); (S.F.); (V.B.); (N.E.-S.); (M.D.)
| | - Nelly Etienne-Selloum
- Laboratory of Bioimaging and Pathology, University of Strasbourg, UMR7021 CNRS, 67401 Illkirch, France; (M.B.); (A.J.); (O.C.); (S.F.); (V.B.); (N.E.-S.); (M.D.)
- Department of Pharmacy, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, France
| | - Alain C. Jung
- Laboratory STREINTH (Stress Response and Innovative Therapies), Inserm IRFAC U1113, Université de Strasbourg, 67200 Strasbourg, France; (A.C.J.); (C.M.); (S.L.)
- Laboratory of Tumor Biology, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, France
| | - Murielle Masson
- UMR7242 Biotechnologie et Signalisation Cellulaire, Ecole Supérieure de Biotechnologie de Strasbourg, 67412 Illkirch, France;
| | - Christine Macabre
- Laboratory STREINTH (Stress Response and Innovative Therapies), Inserm IRFAC U1113, Université de Strasbourg, 67200 Strasbourg, France; (A.C.J.); (C.M.); (S.L.)
- Laboratory of Tumor Biology, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, France
| | - Sonia Ledrappier
- Laboratory STREINTH (Stress Response and Innovative Therapies), Inserm IRFAC U1113, Université de Strasbourg, 67200 Strasbourg, France; (A.C.J.); (C.M.); (S.L.)
- Laboratory of Tumor Biology, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, France
| | - Hélène Burckel
- Paul Strauss Comprehensive Cancer Center, Radiobiology Laboratory, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg University, UNICANCER, 67000 Strasbourg, France; (H.B.); (C.M.); (G.N.)
| | - Carole Mura
- Paul Strauss Comprehensive Cancer Center, Radiobiology Laboratory, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg University, UNICANCER, 67000 Strasbourg, France; (H.B.); (C.M.); (G.N.)
| | - Georges Noël
- Paul Strauss Comprehensive Cancer Center, Radiobiology Laboratory, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg University, UNICANCER, 67000 Strasbourg, France; (H.B.); (C.M.); (G.N.)
- Paul Strauss Comprehensive Cancer Center, Institut de Cancérologie Strasbourg Europe (ICANS), Department of Radiation Oncology, Unicancer, 67200 Strasbourg, France
| | - Christian Borel
- Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, France;
| | - François Fasquelle
- Institut Pathology, University Hospital of Lausanne, 1011 Lausanne, Switzerland;
| | - Mihaela-Alina Onea
- Department of Pathology, Strasbourg University Hospital, 67200 Strasbourg, France; (M.-A.O.); (M.-P.C.)
| | - Marie-Pierre Chenard
- Department of Pathology, Strasbourg University Hospital, 67200 Strasbourg, France; (M.-A.O.); (M.-P.C.)
| | - Alicia Thiéry
- Department of Public Health, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, France;
| | - Monique Dontenwill
- Laboratory of Bioimaging and Pathology, University of Strasbourg, UMR7021 CNRS, 67401 Illkirch, France; (M.B.); (A.J.); (O.C.); (S.F.); (V.B.); (N.E.-S.); (M.D.)
| | - Sophie Martin
- Laboratory of Bioimaging and Pathology, University of Strasbourg, UMR7021 CNRS, 67401 Illkirch, France; (M.B.); (A.J.); (O.C.); (S.F.); (V.B.); (N.E.-S.); (M.D.)
- Correspondence: ; Tel.: +3-336-885-4197; Fax: +3-336-885-4313
| |
Collapse
|